What human clinical trials exist on C60 supplementation and how were carriers handled?
Executive summary
No completed, controlled human clinical trials testing oral C60 supplementation in healthy people or patients were identified in the provided reporting; most human-relevant work is limited to ex vivo human cell experiments, animal studies, and commercial cosmetic or clinic use [1] [2] [3] [4]. Preclinical and formulation literature shows researchers have repeatedly focused on solubilizing and delivering C60 with carriers—oils, liposomes, micelles, PEGylated conjugates, and self‑microemulsifying systems—because pristine C60 is essentially non‑polar and poorly water soluble [5] [2] [6] [7].
1. There are no robust human clinical trials of C60 “supplementation” in the peer‑reviewed sources provided
A systematic reading of the citations and reviews in the dataset finds human work confined to studies using freshly isolated human cells or to products used in clinics/cosmetics, not to randomized human ingestion trials with controlled dosing and endpoints; sources explicitly state human trials are still lacking or limited to in vitro human cell work and animal experiments [1] [4] [3]. Commercial claims and product use (for example in Japanese cosmetic clinics) are documented, but such use is not the same as published clinical trials demonstrating safety and efficacy after oral supplementation [2] [4].
2. The preclinical record establishes why carriers matter: C60 is hydrophobic and needs formulation to interact with biology
Multiple reviews and modeling studies emphasize that pristine C60 is non‑polar and must be functionalized, complexed with organic molecules, or placed into colloids/micelles to increase water solubility and bioavailability; those formulation steps are foundational to any prospective human dosing because they change distribution, cellular uptake, and reactivity [5] [8] [2]. In vitro and animal efficacy/toxicity reports therefore nearly always test C60 in formulated states rather than as insoluble powder [9] [10].
3. Typical carriers reported in the literature: oils, liposomes, micelles, PEGylation, and SMEDDS
Reports and experimental methods describe oil suspensions (olive/coconut/avocado and laboratory oils) used as simple carriers, liposome complexes, aqueous colloids/micellar formulations such as ExtraOx, PEGylated phospholipid conjugates (DSPE‑PEG‑C60), and self‑microemulsifying drug delivery systems containing Cremophor EL, medium‑chain triglycerides and PEG‑400; each study specifies the carrier used because it determines solubility and cellular exposure [11] [2] [6] [1]. Photodynamic and sonodynamic therapy work often uses colloidal aqueous solutions or engineered nanocomplexes to enable cellular uptake and light/ultrasound activation [12] [13].
4. Carriers change both putative benefits and risk profiles—evidence and open concerns
Analyses flag both promise and hazards: carriers can improve delivery and reduce immediate cytotoxicity of loaded drugs but also alter biodistribution, persistence, interactions with DNA and proteins, and potential nanotoxicity (for example, disruption of DNA G‑quadruplexes or altered protein conformations has been raised as a mechanistic worry for fullerene interactions) [8] [14]. Biodistribution studies in mice show carrier form alters organ accumulation and acute toxicity profiles, and reviews repeatedly call out gaps in elimination, long‑term tissue persistence, sterility and commercial viability as unresolved safety questions before clinical translation [2] [8] [15].
5. Conclusion: commercial supplementation exists, but peer‑reviewed human trials and standardized carrier reporting do not
The evidence base shows active preclinical research and commercial use of C60 in formulated products, and the literature documents a variety of carriers chosen to overcome C60’s hydrophobicity, but no clear published human clinical trials of oral supplementation with controlled designs and detailed carrier characterization are present in the supplied sources [4] [1] [2]. That gap matters because formulation determines exposure and safety; until randomized human studies that specify the C60 species, carrier composition, dosing, sterility and pharmacokinetics are published, claims about benefits or safety of oral C60 supplements remain speculative based on the materials provided [6] [8].